In 1935, two gynaecologists described a medical phenomenon, named it after what they could see, and quietly set reproductive medicine back by nearly a century. This is the story of polycystic ovary syndrome, or PCOS, a condition that affects one in eight women. The “cysts” thought to define the disease are not cysts at all. Instead, they are small, arrested follicles (fluid-filled sacs, each housing an immature egg) that, on ultrasound, ring around the ovarian wall in what clinicians call a “string of pearls.” The poetry, unfortunately, obscured the biology, as this finding appears in only a subset of patients. However, a few months ago, after decades of lobbying from researchers and patient advocates alike, a consensus panel successfully retired the name. The replacement: Polyendocrine Metabolic Ovarian Syndrome, or PMOS.
A name that carries an argument
The new name is not cosmetic. Unpack it and you find a disease redefined. “Polyendocrine” signals that the hormonal disruption extends well beyond the ovary, feeding a dysregulation that no single gland owns. “Metabolic” brings attention to what clinicians had long recognized: that this syndrome is, at its core, a disorder of energy and fuel deserving as much attention in an endocrinology clinic as a reproductive one. “Ovarian” survives, but has been demoted, correctly, to a site of manifestation rather than a source of cause. The ovary, in this framing, is not the origin of the problem. It is one of its most visible victims.
The circuit nobody could see as a whole
The metabolic dimension of PMOS is, by now, reasonably well established. People with the condition are three to four times more likely to develop insulin resistance than their peers, and a substantial proportion will meet criteria for Type 2 diabetes by middle age, figures that rival those seen in populations with longstanding obesity. Elevated insulin stimulates the ovaries to overproduce androgens, which worsen metabolic function, which drives more insulin. It is a feedback loop that hormonal contraceptives, the reflexive first-line treatment for decades, do nothing to interrupt. Metformin, a diabetes drug, often works better, which should have been a clue about the nature of the disease long before it was taken as one.
What the metabolic framing alone still misses, however, is the immunological layer beneath it. People with PMOS carry elevated levels of circulating inflammatory markers, C-reactive protein, interleukin-18, and TNF-alpha, independently of body weight.
This is not the acute inflammation seen in infections. It is something more insidious: a low-grade, chronic immune activation, the biological equivalent of a fire alarm that never quite sounds but never quite goes silent. Visceral fat, present in excess in many people with PMOS, is not passive energy storage tissue. It is immunologically active, populated by macrophages that secrete inflammatory signals directly impairing insulin signalling. Insulin resistance, in turn, amplifies that immune activation. The two dysfunctions do not merely coexist. They sustain each other, cycling through a feedback architecture that endocrinologists and immunologists were each, historically, looking at only half of.
This is the crosstalk that the old name made invisible. PCOS, filed under reproductive medicine, attracted reproductive researchers asking reproductive questions. The metabolic-immune circuit running underneath had to wait for a generation of scientists willing to look across specialty lines, and for a name that told them, finally, where to look.
The word is the map
None of this means the rename alone will accelerate a cure. PMOS still lacks a definitive biomarker, still carries a diagnostic delay measured in years, and still receives research funding that embarrasses itself against the burden of disease it represents. But the name change encodes a hypothesis, and hypotheses have consequences. If PMOS is understood as a systemic disorder of interacting metabolic and immune pathways that announces itself through the ovary, rather than a structural curiosity of the ovary itself, the research questions, clinical collaborations, and drug targets all change. In medicine, what you call something shapes what you look for. For ninety years, researchers looked at the wrong thing. The new name, at minimum, points us in the right direction.
Yashar Aghazadeh Habashi
Latest posts by Yashar Aghazadeh Habashi (see all)
- Endometriosis - October 5, 2026
- PCOS/PMOS and Chronic Low-Grade Inflammation: The Metabolic-Immune Crossover - October 5, 2026
- Undercover in the Uterus - October 5, 2026